TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07355218: A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic

Sponsor: EMD Serono Research & Development Institute, Inc. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 202 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$587,880

Rescue Site Savings

+$391,920

Unlock Full NCT07355218 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07355218 Rescue Dossier →